Mariona Riudavets

Villejuif, 94805, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

New biomarkers for antibody-drug conjugates in lung cancer the pathologist's perspective.

New biomarkers for antibody-drug conjugates in lung cancer the pathologist's perspective.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 15, 2026

Erratum to 'Targeting DLL3: A New Weapon in Lung Neuroendocrine Tumors?' [JTO Clinical and Research Reports Volume 6 Issue 5 (2025) 100796].

Erratum to 'Targeting DLL3: A New Weapon in Lung Neuroendocrine Tumors?' [JTO Clinical and Research Reports Volume 6 Issue 5 (2025) 100796].

Journal: JTO clinical and research reports

Published: June 19, 2025

Gut Dysbiosis as a Potential Guide for Immunotherapy (Dis)Continuation After 2 Years in NSCLC: A Brief Report.

Gut Dysbiosis as a Potential Guide for Immunotherapy (Dis)Continuation After 2 Years in NSCLC: A Brief Report.

Journal: JTO clinical and research reports

Published: June 06, 2025

The rechallenge benefit score: A clinical decision tool for patients progressing after immunotherapy.

The rechallenge benefit score: A clinical decision tool for patients progressing after immunotherapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 28, 2025

Targeting DLL3: A New Weapon in Lung Neuroendocrine Tumors?

Targeting DLL3: A New Weapon in Lung Neuroendocrine Tumors?

Journal: JTO clinical and research reports

Published: April 14, 2025

Treatment with peri-operative immunotherapy of resectable PCNBs

Treatment with peri-operative immunotherapy of resectable PCNBs

Journal: Bulletin du cancer

Published: March 28, 2025

Lung cancer: major epidemiological and therapeutic developments

Lung cancer: major epidemiological and therapeutic developments

Journal: Bulletin du cancer

Published: March 28, 2025

The Era of Antibody Drug Conjugates in Lung Cancer: Trick or Threat?

The Era of Antibody Drug Conjugates in Lung Cancer: Trick or Threat?

Journal: Cancer research and treatment

Published: July 26, 2024

Kinetics of IFNγ-Induced Cytokines and Development of Immune-Related Adverse Events in Patients Receiving PD-(L)1 Inhibitors.

Kinetics of IFNγ-Induced Cytokines and Development of Immune-Related Adverse Events in Patients Receiving PD-(L)1 Inhibitors.

Journal: Cancers

Published: February 29, 2024

Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.

Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.

Journal: Clinical lung cancer

Published: August 22, 2023

An update on lorlatinib: a novel first line treatment for ALK-positive advanced lung cancer.

An update on lorlatinib: a novel first line treatment for ALK-positive advanced lung cancer.

Journal: Expert opinion on pharmacotherapy

Published: December 21, 2022

Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report.

Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report.

Journal: JTO clinical and research reports

Published: September 12, 2022

Showing 1-12 of 30

Last Updated: 09/26/2026